It’s only fair to share… Baricitinib NDA submitted jan 2016 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile, 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl]- 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]- 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile For the treatment of rheumatoid arthritis and diabetic kidney disease Incyte Corporation INNOVATOR http://www.ama-assn.org/resources/doc/usan/baricitinib.pdf MF C16H17N7O2S MW 371.4 SPONSOR Eli Lilly and Company CODE LY3009104, INCB028050 CAS 1187594-09-7 UPDATE……..APPROVED PMDA 2017 WO 2009114512 2-[3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol- 1-yl)-1-(ethylsulfonyl)azetidin-3-yl]acetonitrile (baricitinib) FREE FORM m.p. …